Evaluation of a New Peroral Bronchodilator: Z.1170 (Broxaterol)

Broxaterol (Z.1170), a New Oral <i>β</i>₂-Agonist Compared with Salbutamol

“…As regards the persistence and appearance of the ef fect, no significant difference was found between the 2 drugs. On the whole, our re sults are comparable to those of Minette and Prihadi [3] and Rampulla and Corsico [5].…”

“…Other sources suggest that oral /^-ago nists are not the first-choice drug for treat ment of reversible airway obstruction [3,[6][7][8][9][10][11], Indeed, inhaled agents act directly on the target organ and produce only min imal blood levels, consequently drastically decreasing systemic side effects [12]. It should also be pointed out that the combi nation of /^-agonists with other com pounds (e.g.…”

“…Other authors [3,5], however, in studies carried out with a de sign comparable to ours, rarely noticed tremor after administration of 0.5 mg broxaterol and 4.0 salbutamol and the fre quency of this side effect was almost the same with both drugs: in the first study quoted [3] it was observed in 1 patient out of 20 after the administration of both drugs, in the second study, out of 10 pa tients treated, 2 patients complained of tremors after the administration of broxa terol and 1 after the administration of sal butamol [5]. Taking into account the mi nor clinical significance of these side ef fects, a higher dosage of the oral f a -ago nist could be discussed.…”

“…The potency of the /2-agonistic activity of the new com pound is comparable to that of salbutamol in vitro, but is substantially greater in vivo when administrated orally [1], The doses of broxaterol hydrochloride which proved active in inhibiting induced bronchospasm did not cause any significant modi fication in the heart rate or blood pressure [1], Pilot studies in normal volunteers and in patients with chronic bronchitis have shown a good tolerability of broxaterol hydrochloride 0.5 mg per os: no signifi cant variations of the heart rate or blood pressure were recorded, tremor was ob served with low frequency and always with low intensity, no pathologically sig nificant variation was observed in the blood counts, glycemia and blood chemis tries correlated to the hepatic and renal functions [2], Minette et al [3] observed significant increases in forced expiratory volume in 1 s (FEV|) in 20 patients with chronic obstructive lung disease after the administration of 0.5 mg broxaterol hy drochloride. These effects were compar able to those observed after the adminis tration of 4.0 mg salbutamol.…”

Broxaterol, a New β₂-Adrenoceptor Agonist Compared to Salbutamol in Asthmatics, Oral and Inhalation Treatment

“…Other studies have also evaluated the potency for broxaterol compared to sal butamol and for oral treatment there seems to be agreement that the potency difference is about 8-16 times [6,8]. An other study compared only one dose of each drug, and showed that an 8 times higher dose of salbutamol gave the same bronchodilation as broxaterol [7], How ever, the present study is the only one which has been performed with cumula tively increasing doses of the drugs.…”